WallStreetZenWallStreetZen

NASDAQ: ITOS
Iteos Therapeutics Inc Stock

Open Broker Account
$19.71-0.59 (-2.91%)
Updated Dec 9, 2022
ITOS Price
$19.71
Fair Value Price
$39.69
Market Cap
$701.19M
52 Week Low
$16.21
52 Week High
$52.43
P/E
2.66x
P/B
1.11x
P/S
1.49x
PEG
0.01x
Dividend Yield
N/A
Revenue
$454.23M
Earnings
$261.07M
Gross Margin
100%
Operating Margin
77.06%
Profit Margin
57.5%
Debt to Equity
0.23
Operating Cash Flow
-$143M
Beta
1.14
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ITOS Overview

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ITOS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ITOS ($19.71) is undervalued by 50.34% relative to our estimate of its Fair Value price of $39.69 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ITOS ($19.71) is significantly undervalued by 50.34% relative to our estimate of its Fair Value price of $39.69 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ITOS ($19.71) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ITOS due diligence checks available for Premium users.

Be the first to know about important ITOS news, forecast changes, insider trades & much more!

ITOS News

Valuation

ITOS fair value

Fair Value of ITOS stock based on Discounted Cash Flow (DCF)
Price
$19.71
Fair Value
$39.69
Undervalued by
50.34%
ITOS ($19.71) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ITOS ($19.71) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ITOS ($19.71) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ITOS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
2.66x
Industry
13.17x
Market
21.21x
ITOS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ITOS is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

ITOS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.11x
Industry
4.91x
ITOS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ITOS price to earnings growth (PEG)

For valuing profitable companies with growth potential
ITOS is good value based... subscribe to Premium to read more.
PEG Value Valuation

ITOS's financial health

Profit margin

Revenue
$19.5M
Net Income
$991.0k
Profit Margin
5.1%
ITOS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ITOS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$777.9M
Liabilities
$143.7M
Debt to equity
0.23
ITOS's short-term assets ($768.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ITOS's short-term assets ($768.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ITOS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$29.7M
Investing
-$105.0k
Financing
-$1.0k
ITOS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ITOS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ITOS$701.19M-2.91%2.66x1.11x
CERS$699.04M-0.51%-17.91x9.56x
ADMA$698.56M-2.47%-10.14x6.96x
PNT$697.26M-1.64%-7.59x2.26x
CTIC$695.38M-2.84%-4.98x-41.30x

Iteos Therapeutics Stock FAQ

What is Iteos Therapeutics's quote symbol?

NASDAQ: ITOS) Iteos Therapeutics trades on the NASDAQ under the ticker symbol ITOS. Iteos Therapeutics stock quotes can also be displayed as NASDAQ: ITOS.

If you're new to stock investing, here's how to buy Iteos Therapeutics stock.

What is the 52 week high and low for Iteos Therapeutics (NASDAQ: ITOS)?

(NASDAQ: ITOS) Iteos Therapeutics's 52-week high was $52.43, and its 52-week low was $16.21. It is currently -62.41% from its 52-week high and 21.59% from its 52-week low.

How much is Iteos Therapeutics stock worth today?

(NASDAQ: ITOS) Iteos Therapeutics currently has 35,575,323 outstanding shares. With Iteos Therapeutics stock trading at $19.71 per share, the total value of Iteos Therapeutics stock (market capitalization) is $701.19M.

Iteos Therapeutics stock was originally listed at a price of $19.05 in Jul 24, 2020. If you had invested in Iteos Therapeutics stock at $19.05, your return over the last 2 years would have been 3.46%, for an annualized return of 1.72% (not including any dividends or dividend reinvestments).

How much is Iteos Therapeutics's stock price per share?

(NASDAQ: ITOS) Iteos Therapeutics stock price per share is $19.71 today (as of Dec 9, 2022).

What is Iteos Therapeutics's Market Cap?

(NASDAQ: ITOS) Iteos Therapeutics's market cap is $701.19M, as of Dec 10, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Iteos Therapeutics's market cap is calculated by multiplying ITOS's current stock price of $19.71 by ITOS's total outstanding shares of 35,575,323.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.